Phase III VAYHIT2 data showed that ianalumab, a BAFF‑receptor‑targeting monoclonal antibody, delivered prolonged disease control in immune thrombocytopenia (ITP), with over half of patients sustaining safe platelet counts for at least one year after a limited treatment course. The trial randomized 152 adults and was presented at ASH and published in the New England Journal of Medicine. Ianalumab’s mechanism depletes autoreactive B cells by targeting the BAFF receptor; this differs from ongoing TPO‑agonist therapies that require chronic dosing. Lead investigators and Penn researchers emphasized the potential for durable, finite courses to change long‑term disease management. If regulators grant approvals, ianalumab could reduce chronic therapy burden for many ITP patients and shift treatment paradigms toward time‑limited immunomodulation.